|
US6506798B1
(en)
|
1997-07-01 |
2003-01-14 |
Warner-Lambert Company |
4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
|
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
|
TR200101704T2
(tr)
*
|
1998-12-15 |
2001-11-21 |
Warner-Lambert Company |
Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
|
|
AU2203800A
(en)
*
|
1999-01-07 |
2000-07-24 |
Warner-Lambert Company |
Antiviral method using mek inhibitors
|
|
GEP20032999B
(en)
*
|
1999-01-13 |
2003-06-25 |
Warner Lambert Co |
1-Heterocycle Substituted Diarylamines
|
|
IL144214A0
(en)
|
1999-01-13 |
2002-05-23 |
Warner Lambert Co |
Benzoheterocycles and their use as mek inhibitors
|
|
CA2348236A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Stephen Douglas Barrett |
4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
|
|
CA2349467A1
(en)
|
1999-01-13 |
2000-07-20 |
Warner-Lambert Company |
Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
|
|
AU2201500A
(en)
|
1999-01-13 |
2000-08-01 |
Warner-Lambert Company |
Benzenesulfonamide derivatives and their use as mek inhibitors
|
|
PL351085A1
(en)
*
|
1999-04-21 |
2003-03-24 |
Warner Lambert Co |
Method for making 2-(n-phenylamino)benzoic acids
|
|
US6686499B1
(en)
|
1999-04-21 |
2004-02-03 |
Warner-Lambert Company |
Method for making 2-(N-phenylamino)benzoic acids
|
|
GB9910577D0
(en)
*
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
|
KR20020012315A
(ko)
*
|
1999-07-16 |
2002-02-15 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
Ｍｅｋ 저해제를 사용한 만성 통증의 치료 방법
|
|
AU2001247372A1
(en)
*
|
2000-03-15 |
2001-09-24 |
Warner Lambert Company |
5-amide substituted diarylamines as mex inhibitors
|
|
US7001905B2
(en)
|
2000-03-15 |
2006-02-21 |
Warner-Lambert Company |
Substituted diarylamines as MEK inhibitors
|
|
DE10017480A1
(de)
*
|
2000-04-07 |
2001-10-11 |
Transmit Technologietransfer |
Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
|
|
WO2002006213A2
(en)
*
|
2000-07-19 |
2002-01-24 |
Warner-Lambert Company |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
KR20030059115A
(ko)
*
|
2000-08-25 |
2003-07-07 |
워너-램버트 캄파니 엘엘씨 |
Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법
|
|
EP1365796A2
(en)
|
2000-09-01 |
2003-12-03 |
Van Andel Institute |
Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
|
|
AU2001295791A1
(en)
|
2000-11-02 |
2002-05-15 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
|
AU2002210714A1
(en)
|
2000-11-02 |
2002-06-11 |
Astrazeneca Ab |
Substituted quinolines as antitumor agents
|
|
EP1377312A4
(en)
*
|
2001-03-22 |
2004-10-06 |
Andel Inst Van |
ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS
|
|
IL149462A0
(en)
|
2001-05-09 |
2002-11-10 |
Warner Lambert Co |
Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
|
|
DOP2003000556A
(es)
|
2002-01-23 |
2003-10-31 |
Warner Lambert Co |
Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
|
|
BR0307060A
(pt)
*
|
2002-01-23 |
2004-10-26 |
Warner Lambert Co |
ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
|
|
TWI343377B
(en)
|
2002-03-13 |
2011-06-11 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
BRPI0412851A
(pt)
|
2003-07-24 |
2006-10-03 |
Warner Lambert Co |
benzamidazóis de n-metila-substituìdos
|
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
WO2005028426A1
(ja)
|
2003-09-19 |
2005-03-31 |
Chugai Seiyaku Kabushiki Kaisha |
新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
|
|
BRPI0415710A
(pt)
|
2003-10-21 |
2006-12-19 |
Warner Lambert Co |
formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
NZ547481A
(en)
|
2003-11-19 |
2009-12-24 |
Array Biopharma Inc |
Heterocyclic inhibitors of mek and methods of use thereof
|
|
US7732616B2
(en)
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
US20050130954A1
(en)
|
2003-11-21 |
2005-06-16 |
Mitchell Ian S. |
AKT protein kinase inhibitors
|
|
UA89035C2
(ru)
|
2003-12-03 |
2009-12-25 |
Лео Фарма А/С |
Эфиры гидроксамовых кислот и их фармацевтическое применение
|
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
TWI361066B
(en)
|
2004-07-26 |
2012-04-01 |
Chugai Pharmaceutical Co Ltd |
5-substituted-2-phenylamino benzamides as mek inhibitors
|
|
BRPI0514515A
(pt)
|
2004-08-17 |
2008-06-10 |
Hoffmann La Roche |
hidantoìnas substituìdas
|
|
TW200621766A
(en)
*
|
2004-09-17 |
2006-07-01 |
Hoffmann La Roche |
Substituted hydantoins
|
|
AR051248A1
(es)
|
2004-10-20 |
2007-01-03 |
Applied Research Systems |
Derivados de 3-arilamino piridina
|
|
WO2006109661A1
(ja)
|
2005-04-06 |
2006-10-19 |
Chugai Seiyaku Kabushiki Kaisha |
２，３，４－トリフルオロ－５－（ヨード又はブロモ）安息香酸の製造方法
|
|
CN102898364A
(zh)
|
2005-05-18 |
2013-01-30 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
|
CN103524392B
(zh)
|
2005-10-07 |
2018-06-01 |
埃克塞利希斯股份有限公司 |
作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
|
|
US7612212B2
(en)
|
2006-02-22 |
2009-11-03 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
JPWO2007132867A1
(ja)
|
2006-05-15 |
2009-09-24 |
杉本 芳一 |
癌の予防及び治療剤
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
WO2008006032A1
(en)
|
2006-07-06 |
2008-01-10 |
Array Biopharma Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
CN101511842B
(zh)
|
2006-07-06 |
2012-10-31 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶
|
|
EP1908751A1
(en)
*
|
2006-10-03 |
2008-04-09 |
EOS S.p.A. |
N-hydroxy benzamides with antitumour activity
|
|
NZ577047A
(en)
|
2006-10-23 |
2011-02-25 |
Takeda Pharmaceutical |
Mapk/erk kinase inhibitors
|
|
ES2703723T3
(es)
|
2006-12-14 |
2019-03-12 |
Exelixis Inc |
Métodos para usar inhibidores de MEK
|
|
WO2008075741A1
(ja)
*
|
2006-12-20 |
2008-06-26 |
Keio University |
糖尿病治療剤及び予防剤
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US8618097B2
(en)
|
2007-07-05 |
2013-12-31 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
SI2173723T1
(sl)
|
2007-07-05 |
2011-12-30 |
Array Biopharma Inc |
Pirimidil ciklopentani kot inhibitorji AKT-protein-kinaze
|
|
CN101778839A
(zh)
|
2007-08-16 |
2010-07-14 |
霍夫曼-拉罗奇有限公司 |
取代的乙内酰脲
|
|
WO2009080523A1
(en)
|
2007-12-20 |
2009-07-02 |
F. Hoffmann-La Roche Ag |
Substituted hydantoins as mek kinase inhibitors
|
|
JP5346345B2
(ja)
|
2008-01-09 |
2013-11-20 |
アレイ バイオファーマ、インコーポレイテッド |
Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
|
|
EP2240455B1
(en)
|
2008-01-09 |
2012-12-26 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
|
|
US8530457B2
(en)
|
2008-05-20 |
2013-09-10 |
Fox Chase Cancer Center |
Method for the treatment of lymphangioleiomyomatosis (LAM)
|
|
SI2307376T1
(sl)
|
2008-08-04 |
2016-02-29 |
Merck Patent Gmbh |
Nove spojine fenilamino izonikotinamida
|
|
US8350026B2
(en)
|
2008-08-27 |
2013-01-08 |
Leo Pharma A/S |
VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
|
EP2346818B1
(en)
|
2008-11-10 |
2012-12-05 |
Bayer Intellectual Property GmbH |
Substituted sulphonamido phenoxybenzamides
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
WO2011047796A1
(en)
|
2009-10-21 |
2011-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted halophenoxybenzamide derivatives
|
|
EP2491016A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
EP3028699B1
(en)
|
2010-02-25 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
EP2545187B1
(en)
|
2010-03-09 |
2018-09-05 |
Dana-Farber Cancer Institute, Inc. |
Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
|
|
CA2816188A1
(en)
|
2010-10-29 |
2012-05-03 |
Marion Hitchcock |
Substituted phenoxypyridines
|
|
AU2011349446C1
(en)
|
2010-12-22 |
2016-01-21 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
|
|
ES2620644T3
(es)
|
2011-04-01 |
2017-06-29 |
Genentech, Inc. |
Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
|
|
KR20140022053A
(ko)
|
2011-04-01 |
2014-02-21 |
제넨테크, 인크. |
Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
|
|
CA2836364C
(en)
|
2011-05-25 |
2021-01-26 |
Universite Paris Descartes |
Erk inhibitors for use in treating spinal muscular atrophy
|
|
CN103204822B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途
|
|
WO2013169858A1
(en)
|
2012-05-08 |
2013-11-14 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
HRP20180670T1
(hr)
|
2012-10-12 |
2018-07-13 |
Exelixis Inc. |
Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
|
|
WO2015038704A1
(en)
|
2013-09-11 |
2015-03-19 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
|
WO2016123100A1
(en)
|
2015-01-26 |
2016-08-04 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
CA3001917A1
(en)
|
2015-10-16 |
2017-04-20 |
Fate Therapeutics, Inc. |
Platform for the induction & maintenance of ground state pluripotency
|
|
CN108368520B
(zh)
|
2015-11-04 |
2023-01-17 |
菲特治疗公司 |
多能细胞的基因组工程改造
|
|
WO2017078807A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
SG11201805186VA
(en)
|
2016-01-20 |
2018-07-30 |
Fate Therapeutics Inc |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
KR20190070912A
(ko)
*
|
2016-07-28 |
2019-06-21 |
더 존스 홉킨스 유니버시티 |
O-치환된 히드록삼산
|
|
JP7098615B2
(ja)
|
2016-12-05 |
2022-07-11 |
フェイト セラピューティクス，インコーポレイテッド |
養子免疫療法における免疫細胞調節のための組成物および方法
|
|
CN107556201B
(zh)
*
|
2017-09-08 |
2020-10-27 |
山西智创药研科技有限公司 |
一种制备间氨基苯酚的工艺方法
|
|
JP7546297B2
(ja)
*
|
2018-11-20 |
2024-09-06 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚障害の処置のためのチエニル－アニリン化合物
|
|
CA3120351A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
EP3942045A1
(en)
|
2019-03-21 |
2022-01-26 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|